TY - JOUR
T1 - Advances in Alport syndrome diagnosis using next-generation sequencing
AU - Artuso, Rosangela
AU - Fallerini, Chiara
AU - Dosa, Laura
AU - Scionti, Francesca
AU - Clementi, Maurizio
AU - Garosi, Guido
AU - Massella, Laura
AU - Epistolato, Maria Carmela
AU - Mancini, Roberta
AU - Mari, Francesca
AU - Longo, Ilaria
AU - Ariani, Francesca
AU - Renieri, Alessandra
AU - Bruttini, Mirella
PY - 2012/1
Y1 - 2012/1
N2 - Alport syndrome (ATS) is a hereditary nephropathy often associated with sensorineural hypoacusis and ocular abnormalities. Mutations in the COL4A5 gene cause X-linked ATS. Mutations in COL4A4 and COL4A3 genes have been reported in both autosomal recessive and autosomal dominant ATS. The conventional mutation screening, performed by DHPLC and/or Sanger sequencing, is time-consuming and has relatively high costs because of the absence of hot spots and to the high number of exons per gene: 51 (COL4A5), 48 (COL4A4) and 52 (COL4A3). Several months are usually necessary to complete the diagnosis, especially in cases with less informative pedigrees. To overcome these limitations, we designed a next-generation sequencing (NGS) protocol enabling simultaneous detection of all possible variants in the three genes. We used a method coupling selective amplification to the 454 Roche DNA sequencing platform (Genome Sequencer junior). The application of this technology allowed us to identify the second mutation in two ATS patients (p.Ser1147Phe in COL4A3 and p.Arg1682Trp in COL4A4) and to reconsider the diagnosis of ATS in a third patient. This study, therefore, illustrates the successful application of NGS to mutation screening of Mendelian disorders with locus heterogeneity.
AB - Alport syndrome (ATS) is a hereditary nephropathy often associated with sensorineural hypoacusis and ocular abnormalities. Mutations in the COL4A5 gene cause X-linked ATS. Mutations in COL4A4 and COL4A3 genes have been reported in both autosomal recessive and autosomal dominant ATS. The conventional mutation screening, performed by DHPLC and/or Sanger sequencing, is time-consuming and has relatively high costs because of the absence of hot spots and to the high number of exons per gene: 51 (COL4A5), 48 (COL4A4) and 52 (COL4A3). Several months are usually necessary to complete the diagnosis, especially in cases with less informative pedigrees. To overcome these limitations, we designed a next-generation sequencing (NGS) protocol enabling simultaneous detection of all possible variants in the three genes. We used a method coupling selective amplification to the 454 Roche DNA sequencing platform (Genome Sequencer junior). The application of this technology allowed us to identify the second mutation in two ATS patients (p.Ser1147Phe in COL4A3 and p.Arg1682Trp in COL4A4) and to reconsider the diagnosis of ATS in a third patient. This study, therefore, illustrates the successful application of NGS to mutation screening of Mendelian disorders with locus heterogeneity.
KW - Alport syndrome
KW - DNA sequencing
KW - next-generation sequencing
UR - http://www.scopus.com/inward/record.url?scp=83255185118&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=83255185118&partnerID=8YFLogxK
U2 - 10.1038/ejhg.2011.164
DO - 10.1038/ejhg.2011.164
M3 - Article
C2 - 21897443
AN - SCOPUS:83255185118
VL - 20
SP - 50
EP - 57
JO - European Journal of Human Genetics
JF - European Journal of Human Genetics
SN - 1018-4813
IS - 1
ER -